open access

Vol 1, No 4 (2016)
ORIGINAL PAPERS
Published online: 2017-01-20
Get Citation

Non-penetrating phaco-deep sclerectomy with SkGel implantation — long-term observations

Katarzyna Lewczuk, Joanna Jabłońska, Jacek Rudowicz, Marek Rękas
DOI: 10.5603/OJ.2016.0023
·
Ophthalmology J 2016;1(4):115-123.

open access

Vol 1, No 4 (2016)
ORIGINAL PAPERS
Published online: 2017-01-20

Abstract

INTRODUCTION. The aim of this study is to present the efficacy and safety of non-penetrating phaco-deep sclerectomy (PDS) with implantation of an absorbable sodium hyaluronate implant (SkGel/Corneal).

MATERIALS AND METHODS. In a prospective case series study 219 procedures were performed on 176 subjects receiving PDS with SkGel implantation. Indications were uncontrolled primary-open angle glaucoma (POAG) and operable cataract. Data collected included best corrected visual acuity (BCVA), intraocular pressure (IOP), and number of hypotensive medications. Follow-up examinations were performed one and seven days after procedure, then one, three, and six months after, and thereafter every six months. Complete and qualified success (without and with hypotensive medications) was assessed for IOP ≤ 18 mm Hg and IOP ≤ 12 mm Hg.

RESULTS . The mean follow-up was 48.3 } 12.8 months. At 24 months, mean IOP decreased from 19.9 ± 5.0 mm Hg to 13.4 ± 3.1 mm Hg (P < 0.001) (31.8% reduction) and to 13.3 ± 2.7 mm Hg (P = 0.003) and after 60 months (33.2% reduction). At the 24-month follow-up, the average number of anti-glaucoma medications was reduced from 2.3 ± 0.8 to 0.62 ± 0.88 (p < 0.001). Complete and qualified success rates for IOP ≤ 18 mm Hg were 70.1% and 93.0%, respectively. Goniopuncture (23.8%), suturolysis (20.1%), and needling (18.3%) were performed. The most common complication was transient hypotony (36.07%).

CONCLUSIONS. PDS with SkGel leads to an effective decrease in IOP over a long-term follow-up. The profile of the complications indicates that it is a safe procedure.

Abstract

INTRODUCTION. The aim of this study is to present the efficacy and safety of non-penetrating phaco-deep sclerectomy (PDS) with implantation of an absorbable sodium hyaluronate implant (SkGel/Corneal).

MATERIALS AND METHODS. In a prospective case series study 219 procedures were performed on 176 subjects receiving PDS with SkGel implantation. Indications were uncontrolled primary-open angle glaucoma (POAG) and operable cataract. Data collected included best corrected visual acuity (BCVA), intraocular pressure (IOP), and number of hypotensive medications. Follow-up examinations were performed one and seven days after procedure, then one, three, and six months after, and thereafter every six months. Complete and qualified success (without and with hypotensive medications) was assessed for IOP ≤ 18 mm Hg and IOP ≤ 12 mm Hg.

RESULTS . The mean follow-up was 48.3 } 12.8 months. At 24 months, mean IOP decreased from 19.9 ± 5.0 mm Hg to 13.4 ± 3.1 mm Hg (P < 0.001) (31.8% reduction) and to 13.3 ± 2.7 mm Hg (P = 0.003) and after 60 months (33.2% reduction). At the 24-month follow-up, the average number of anti-glaucoma medications was reduced from 2.3 ± 0.8 to 0.62 ± 0.88 (p < 0.001). Complete and qualified success rates for IOP ≤ 18 mm Hg were 70.1% and 93.0%, respectively. Goniopuncture (23.8%), suturolysis (20.1%), and needling (18.3%) were performed. The most common complication was transient hypotony (36.07%).

CONCLUSIONS. PDS with SkGel leads to an effective decrease in IOP over a long-term follow-up. The profile of the complications indicates that it is a safe procedure.

Get Citation

Keywords

non-penetrating phaco-deep sclerectomy, SkGel implant, primary open angle glaucoma, cataract surgery

About this article
Title

Non-penetrating phaco-deep sclerectomy with SkGel implantation — long-term observations

Journal

Ophthalmology Journal

Issue

Vol 1, No 4 (2016)

Pages

115-123

Published online

2017-01-20

DOI

10.5603/OJ.2016.0023

Bibliographic record

Ophthalmology J 2016;1(4):115-123.

Keywords

non-penetrating phaco-deep sclerectomy
SkGel implant
primary open angle glaucoma
cataract surgery

Authors

Katarzyna Lewczuk
Joanna Jabłońska
Jacek Rudowicz
Marek Rękas

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

VM Media sp. z o.o. VM Group sp.k., Grupa Via Medica, 73 Świętokrzyska St., 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl